Anatomage Revives Heart Beat of a Cadaver

What Kind of Equipment is Used to Analyze DNA?

Below are some of a few basic processes followed throughout DNA testing. The general procedure entails:  • Isolating DNA from a sample containing the needed...

mJOULE Launches in the United Kingdom Reports Sciton

"Sciton is dedicated to worldwide support and growth. We continue to demonstrate our commitment to developing high quality devices and marketing efforts for our physician and medspa partners worldwide." says Lacee J. Naik, Vice President of Marketing and Public Relations.

FDA Issues Draft Guidance on Remanufacturing and Discussion Paper Seeking Feedback on Cybersecurity Servicing of Medical Devices

With this in mind, the FDA is issuing today's draft guidance to help clarify whether activities performed on medical devices are likely remanufacturing as well as a discussion paper on cybersecurity servicing of devices.

Anatomage Inc. today announced it has digitally restored a cadaver’s heart to beat again.Anatomage develops digital cadavers, which are available on the Anatomage Table. These cadavers are accurately reconstructed from preserved human bodies and serve as precise references for anatomical studies. The digital bodies have more than 2,500 anatomical structures that are highly detailed and segmented. Each cadaver has a fully detailed cardiovascular system including not only intricately traced arteries and veins, but also segmented chambers, valves, and cardiac conduction branches.

Anatomage is now able to make a cadaver heart go through a normal cardiac cycle. This innovation is made possible by combining the digital modeling of 3D cardiac CT data and accurate anatomical details from an Anatomage cadaver. Using normal CT images of a heart and statistical models, Anatomage estimated the shape of a heart’s four chambers and digitally simulated the cardiac cycle’s systole and diastole phases. Valve motions, vascular connectivity, and cardiology nerves were accurately modeled,  then integrated into the beating heart chambers. The result is a comprehensively detailed 3D heart of the cadaver that beats in a highly accurate manner.

This new technology is part of the upcoming Table 7 software release for the Anatomage Table. For the first time, digital cadavers are incorporated with physiological contents such as nerve distribution, cardiovascular function, and physiological simulations. Anatomage’s digital cadavers serve as premier tools for medical education, device development, research, and training.

“We are excited that we have achieved real human functions on a cadaver. This is the first time in history that the cadaver has demonstrated a full cardiac cycle in digital simulation – an important beginning. Digital modeling and simulation of physical behavior is a common practice in engineering. It started as crude and simple modeling, but digital modeling and simulations have become so sophisticated that they are replacing physical testings. We believe similar progress will happen in medical applications. We are introducing digital modeling and simulation that are created from real physical bodies. This could serve as the foundation for medical device development, research, education, and training. Currently, live animal bodies or real human cadavers are used for such purposes. With our technology, we can reduce these cadaver-based procedures while increasing digital modeling and simulations. As our technology progresses, we will resurrect the dead body into the digital world.” Jack Choi, CEO of Anatomage.

Click here for Table 7 updates.

spot_img

DON'T MISS

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

One Drop Reports Carrie Siragusa, CPA Appointed VP of Commercial Strategy, Biosensor

Formerly Head of Innovation and Diabetes Portfolio at Sanofi, Siragusa will be part of a team bringing a multi-analyte dermal sensor (biosensor) with continuous health sensing capabilities to market with a mission to provide broader access to continuous glucose monitoring.

Barbara Moorhouse Appointed as Medica Non-Executive Director

Barbara has extensive business and management experience in the private, public, and regulated sectors.

Subscribe to Medical Device News Magazine here.

Related Articles